Patents by Inventor Juergen Hermanns
Juergen Hermanns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130217067Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.Type: ApplicationFiled: February 29, 2012Publication date: August 22, 2013Applicant: GlycoFi, Inc.Inventors: TILLMAN U. GERNGROSS, Stefan Wildt, Byung-kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R. Hamilton, Robert C. Davidson
-
Patent number: 8465586Abstract: The present invention relates to polysaccharide derivatives having an adjusted particle morphology for use in the preparation of a hydraulic setting composition having an adjusted lump rating. The invention further relates to a method of adjusting the lump rating of a hydraulic setting composition comprising adjusting the particle morphology of a particulate polysaccharide derivative. Furthermore, the invention is directed to a hydraulic setting composition comprising a particulate polysaccharide derivative having an adjusted particle morphology. The invention is also directed to various uses of the particulate polysaccharide derivative having an adjusted particle morphology.Type: GrantFiled: July 19, 2011Date of Patent: June 18, 2013Assignee: Dow Global Technologies LLCInventors: Robert Baumann, Yvonne Goerlach-Doht, Marco Grosstueck, Juergen Hermanns, Joerg Neubauer
-
Patent number: 8445227Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII activity, which produce bisected N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.Type: GrantFiled: August 13, 2009Date of Patent: May 21, 2013Assignee: Merck Sharp & DohmeInventors: Piotr Bobrowicz, Stephen R. Hamilton, Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Robert C. Davidson
-
Publication number: 20130112787Abstract: In a process for producing a particulate polysaccharide derivative by dry-grinding a moist polysaccharide derivative, one or more of the properties selected from median diameter, median length, bulk density and dissolution rate is controlled by controlling the temperature of the polysaccharide derivative prior to thy-grinding. Advantageously one or more of the properties selected from median diameter, median length, bulk density and dissolution rate of the particles after thy-grinding is adjusted to a first value by a first temperature of the polysaccharide derivative prior to thy-grinding and is adjusted to a second value by a second temperature.Type: ApplicationFiled: July 28, 2010Publication date: May 9, 2013Inventors: Peter E. Pierini, Yvonne M. Goerlach-Doht, Juergen Hermanns
-
Publication number: 20120187225Abstract: In a process for producing a particulate polysaccharide derivative by dry-grinding a moist polysaccharide derivative the median length of the particles after dry-grinding is controlled by controlling the moisture content of the polysaccharide derivative prior to dry-grinding. Advantageously the median length of the particles after dry-grinding is adjusted to a first value by a first moisture content of the polysaccharide derivative prior to dry-grinding and is adjusted to a second value by a second moisture content.Type: ApplicationFiled: August 31, 2010Publication date: July 26, 2012Applicant: Dow Global Technologies Inc.Inventors: Yvonne M. Goerlach-Doht, Juergen Hermanns
-
Publication number: 20120052530Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.Type: ApplicationFiled: June 9, 2011Publication date: March 1, 2012Applicant: GlycoFi, Inc.Inventors: TILLMAN U. GERNGROSS, Stefan Wildt, Byung-kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R. Hamilton, Robert C. Davidson
-
Publication number: 20120024199Abstract: The present invention relates to polysaccharide derivatives having an adjusted particle morphology for use in the preparation of a hydrolytically setting composition having an adjusted lump rating. The invention further relates to a method of adjusting the lump rating of a hydrolytically setting composition comprising adjusting the particle morphology of a particulate polysaccharide derivative. Furthermore, the invention is directed to a hydrolytically setting composition comprising a particulate polysaccharide derivative having an adjusted particle morphology. The invention is also directed to various uses of the particulate polysaccharide derivative having an adjusted particle morphology.Type: ApplicationFiled: July 19, 2011Publication date: February 2, 2012Inventors: Jörg Neubauer, Yvonne Görlach-Doht, Marco Großstück, Jürgen Hermanns, Robert BAUMANN
-
Publication number: 20120029091Abstract: A method of controlling or adjusting release of an active ingredient from a dosage form comprising the active ingredient and a polysaccharide derivative has been found. The method comprises the steps of a) providing a composition comprising a polysaccharide derivative and a controlled amount of a liquid diluent, based on the dry weight of the polysaccharide derivative, b) subjecting the composition to a dry-grinding operation to provide a dry-ground polysaccharide derivative, and c) incorporating the dry-ground polysaccharide derivative and an active ingredient into a dosage form.Type: ApplicationFiled: June 9, 2011Publication date: February 2, 2012Inventors: Yvonne M. Goerlach-Doht, Juergen Hermanns, Nicholas S. Grasman
-
Patent number: 8067551Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.Type: GrantFiled: November 7, 2008Date of Patent: November 29, 2011Assignee: Glycofi, Inc.Inventors: Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R Hamilton, Robert C. Davidson
-
Patent number: 7935513Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.Type: GrantFiled: June 5, 2008Date of Patent: May 3, 2011Assignee: Glycofi, Inc.Inventors: Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R. Hamilton, Robert C. Davidson
-
Publication number: 20110053214Abstract: The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal ?-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.Type: ApplicationFiled: July 21, 2010Publication date: March 3, 2011Applicant: GLYCOFI, INC.Inventors: Robert Collier Davidson, Tillman Ulf Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen Robin Hamilton
-
Publication number: 20110007148Abstract: The invention relates to a novel inspection device for bottles or similar containers (2), comprising a transport section (4) the containers (2) and comprising a camera system (9) for creating images of at least one region of the containers (2) being moved past the camera system (9).Type: ApplicationFiled: March 18, 2009Publication date: January 13, 2011Inventors: Jürgen Hermann, Horst Böcker
-
Patent number: 7795002Abstract: The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal ?-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.Type: GrantFiled: April 15, 2005Date of Patent: September 14, 2010Assignee: Glycofi, Inc.Inventors: Robert Davidson, Tillman Ulf Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen Robin Hamilton
-
Publication number: 20100016561Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII activity, which produce bisected N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.Type: ApplicationFiled: August 13, 2009Publication date: January 21, 2010Applicant: GlycoFi, Inc.Inventors: Piotr Bobrowicz, Stephen R. Hamilton, Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Robert C. Davidson
-
Publication number: 20090226959Abstract: The present invention relates to eukaryotic host cells, especially lower eukaryotic host cells, having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar and sugar nucleotide transporters to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII, GnTIV, GnTV, GnT VI or GnTIX activity, which produce bisected and/or multiantennary N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar, sugar nucleotide transporters, to yield human-like glycoproteins.Type: ApplicationFiled: November 21, 2008Publication date: September 10, 2009Inventors: Piotr Bobrowicz, Stephen R. Hamilton, Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Robert C. Davidson
-
Publication number: 20090209024Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.Type: ApplicationFiled: June 5, 2008Publication date: August 20, 2009Inventors: Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R. Hamilton, Robert C. Davidson
-
Publication number: 20090155847Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.Type: ApplicationFiled: November 7, 2008Publication date: June 18, 2009Inventors: Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R. Hamilton, Robert C. Davidson
-
Patent number: 7449308Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.Type: GrantFiled: February 20, 2003Date of Patent: November 11, 2008Assignee: GlycoFi, Inc.Inventors: Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R. Hamilton, Robert C. Davidson
-
Patent number: 6698253Abstract: A method of and an arrangement for designing tubular round knitted products on a flat knitting machine operates with the fine automation degree and a plurality of representing, designing and correcting possibilities.Type: GrantFiled: October 2, 2002Date of Patent: March 2, 2004Assignee: H. Stoll GmbH & Co.Inventors: Thomas Stoll, Juergen Hermann, Horst Fries, Hermann Weiss, Michael Haug, Gerhard Ertl
-
Publication number: 20040018590Abstract: The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man5GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g.Type: ApplicationFiled: February 20, 2003Publication date: January 29, 2004Inventors: Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Piotr Bobrowicz, Stephen R. Hamilton, Robert C. Davidson